PMID: 9549633Apr 29, 1998Paper

A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects

Journal of Clinical Pharmacology
D E SalazarP H Slugg

Abstract

The objective of this study was to assess the pharmacokinetics and pharmacodynamics of the dextro (d-) isomer of sotalol, a class III antiarrhythmic agent, in healthy young men and women after a single intravenous bolus dose. The design was open-label, randomized, parallel group. Each group (4 men and 4 women) received either 0.5, 1.5, or 3.0 mg/kg d-sotalol as an intravenous infusion for 2 minutes. Serial measurements of the d-sotalol plasma concentration and the Q-Tc interval data were recorded before, during, and for 72 hours after drug administration. The pharmacokinetics of d-sotalol were found to be well described by a three-compartment model with linear elimination clearance from the central compartment. There were no significant differences in the elimination clearance or volume of the central compartment between dose levels or between men and women. However, women were found to have a lower steady-state volume of distribution than men (1.20 L/Kg versus 1.43 L/Kg). The Q-Tc versus d-sotalol plasma concentration data were fitted to a model that assumed a distinct "effect compartment" and sigmoidal Emax response. The baseline Q-Tc, determined from the fittings, was found to be significantly higher in women (0.40 versus 0....Continue Reading

References

Mar 22, 1976·European Journal of Clinical Pharmacology·H C BrownR G Shanks
Jul 1, 1987·Journal of the American College of Cardiology·J M McCombH Garan
Jul 7, 1994·The New England Journal of Medicine·S H Hohnloser, R L Woosley
Dec 1, 1993·JAMA : the Journal of the American Medical Association·R R MakkarM H Lehmann
Jul 1, 1993·Clinical Pharmacology and Therapeutics·W J Jusko
Apr 1, 1993·Clinical Pharmacology and Therapeutics·S U YasudaR L Woosley

❮ Previous
Next ❯

Citations

Jan 10, 2002·Journal of Pharmaceutical Sciences·Bernd Meibohm, Hartmut Derendorf
Sep 25, 2012·Journal of Electrocardiology·Norman StockbridgeMarek Malik
Dec 21, 2007·Journal of Clinical Pharmacology·Christine E GarnettJogarao V Gobburu
Jan 29, 2011·British Journal of Clinical Pharmacology·Daniel F B WrightStephen B Duffull
Feb 28, 2020·Chirality·Vinod Kumar Vashistha, Anuj Kumar
Aug 22, 2012·British Journal of Clinical Pharmacology·Rashmi R Shah, Joel Morganroth
Nov 26, 2011·Expert Review of Clinical Pharmacology·Ameeta ParekhDouglas C Throckmorton
Oct 30, 2020·Journal of Pharmacokinetics and Pharmacodynamics·Georg FerberJiang Liu
Jun 12, 2021·Critical Care : the Official Journal of the Critical Care Forum·Josée BouchardUNKNOWN EXTRIP workgroup

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Related Papers

International Journal of Clinical Pharmacology and Therapeutics
R NagataJ D Rafizadeh-Kabe
American Journal of Therapeutics
John C SombergJanos Molnar
British Journal of Clinical Pharmacology
Daniel F B Wright, E J Begg
Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas
J O Auler JúniorS R Santos
© 2022 Meta ULC. All rights reserved